Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Oncology

What Are the ELN Risk Categories in AML?

At a Glance

In acute myeloid leukemia (AML), the ELN risk categories—favorable, intermediate, and adverse—describe the genetic makeup of your leukemia cells. This classification tells your oncologist how the disease will respond to chemotherapy and whether you need a stem cell transplant for a long-term cure.

In this answer

3 sections

01

How You Find Out Your Risk Category

02

The Three ELN Risk Categories

03

The Wildcard: Measurable Residual Disease (MRD)

When you are diagnosed with acute myeloid leukemia (AML), your care team will classify your disease into one of three risk categories: favorable, intermediate, or adverse [1][2]. This grouping is based on the European LeukemiaNet (ELN) guidelines, the international rulebook oncologists use to understand the specific genetic “fingerprint” of your leukemia cells [1].

It is important to know that this risk category does not describe how physically sick you feel or how advanced the cancer is. Instead, it tells your doctor how the leukemia is likely to respond to standard chemotherapy, and whether you will need a stem cell transplant or targeted therapies to achieve a long-term cure [3][4].

How You Find Out Your Risk Category

Your ELN category is determined by looking closely at your bone marrow biopsy results. Doctors use specialized lab tests—often called cytogenetics (to look at your chromosomes) and molecular testing or an NGS panel (Next-Generation Sequencing, to look at specific gene mutations) [1].

A note on timing: While some initial results come back quickly, comprehensive genetic testing can take a few weeks. It is very common for patients to start initial treatment before their exact ELN risk category is fully known. Your team will adjust your treatment plan as these detailed lab reports come in.

The Three ELN Risk Categories

AML is not just one disease. The leukemia cells carry specific genetic mutations and chromosomal changes that dictate how the disease behaves [1]. Based on the 2022 ELN guidelines, here is what each category means for your path forward:

Favorable Risk

If your AML is classified as favorable risk, it means the genetic makeup of your leukemia cells (such as specific NPM1 or CEBPA mutations) makes them highly sensitive to standard treatments [5][2].

  • What it means for treatment: Patients in this group have a high chance of being cured with standard, intensive chemotherapy alone [6][3].
  • Stem cell transplant: You generally will not need a donor stem cell transplant—known medically as an allogeneic HSCT (using healthy cells from a donor)—after reaching your first remission [7][8]. For favorable-risk patients, the risk of complications from a transplant usually outweighs the potential benefits [6].

Intermediate Risk

Intermediate risk is the “gray area” of AML [7][9]. The leukemia cells do not have the highly sensitive mutations seen in favorable risk, but they also lack the highly resistant changes seen in adverse risk. For example, intermediate-risk AML often involves a mutation called FLT3-ITD [7].

  • What it means for treatment: You will likely still receive standard chemotherapy to achieve remission, often combined with a targeted therapy pill (like an FLT3 inhibitor) to directly attack the mutation [10][11].
  • Stem cell transplant: Because there is a higher risk of the leukemia returning, doctors often consider a donor stem cell transplant once you are in remission [12][9]. However, this decision is highly individualized. If testing shows your body has completely cleared the leukemia cells, you may be able to safely avoid a transplant [7].

Adverse Risk

Adverse risk means the leukemia cells contain complex chromosomal changes or stubborn mutations (such as TP53 or myelodysplasia-related genes) that make the disease resistant to standard chemotherapy [1][13][14].

  • What it means for treatment: Because standard chemotherapy is less effective, your care team will rely heavily on a precision medicine approach [15][16]. This often involves adding targeted therapies or utilizing lower-intensity treatments (like the drug venetoclax combined with other agents) that are gentler on the body but highly effective against these specific leukemia cells [10][17].
  • Stem cell transplant: For adverse-risk AML, a donor stem cell transplant is usually recommended as the most reliable pathway to long-term remission [18][19]. The primary goal of your initial therapy is to control the disease well enough to safely bridge you to this transplant [20][21].

The Wildcard: Measurable Residual Disease (MRD)

While your ELN risk category creates the initial blueprint for your treatment, your long-term plan can change based on your Measurable Residual Disease (MRD) [5][22].

MRD testing looks for microscopic, leftover leukemia cells in your bone marrow after your initial round of treatment [23].

  • If you are in the favorable risk group but test positive for MRD after chemotherapy, your risk of relapse increases. In this scenario, your doctor may change course and recommend a stem cell transplant [5][2].
  • If you are in the intermediate risk group but test perfectly negative for MRD, your doctor might decide a transplant is unnecessary [7].
  • For all risk groups, ongoing MRD monitoring helps your care team dynamically adjust your treatment and catch potential issues long before they show up on standard tests [24][25].

Common questions in this guide

How do doctors determine my AML risk category?
Your care team determines your ELN risk category by analyzing your bone marrow biopsy results. They use specialized lab tests like cytogenetics and Next-Generation Sequencing (NGS) to look at the specific chromosomes and gene mutations in your leukemia cells.
What does it mean to have favorable risk AML?
Favorable risk means the genetic makeup of your leukemia cells makes them highly sensitive to standard chemotherapy. Patients in this group have a high chance of being cured without needing a donor stem cell transplant.
Will I need a stem cell transplant for intermediate risk AML?
Intermediate risk AML is considered a gray area, and a donor stem cell transplant is often considered once you reach remission. However, this decision is highly individualized and depends on follow-up tests, like whether your body has completely cleared the microscopic leukemia cells.
How is adverse risk AML treated?
Adverse risk AML is often resistant to standard chemotherapy, so doctors typically rely on targeted therapies or lower-intensity treatments. The primary goal is usually to control the leukemia well enough to safely proceed to a donor stem cell transplant for long-term remission.
What is Measurable Residual Disease (MRD) testing?
MRD testing looks for microscopic, leftover leukemia cells in your bone marrow after your initial treatment. Your MRD results can change your long-term plan, such as indicating you need a stem cell transplant even if you were initially in the favorable risk group.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my bone marrow biopsy and NGS panel, what is my ELN risk category?
  2. 2.What exact genetic mutations or chromosomal changes were found in my leukemia cells?
  3. 3.Are there any targeted therapies (like a daily pill) available for my specific mutation profile?
  4. 4.Given my risk category and overall health, are we aiming for a stem cell transplant, or standard chemotherapy?
  5. 5.How and when will we test for Measurable Residual Disease (MRD) to track how well my treatment is working?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can You Be Diagnosed with AML with Less Than 20% Blasts?Does AML Chemotherapy Cause Long-Term Heart Problems?Does the Treatment Center Matter for AML Survival?How Do FLT3 and NPM1 Mutations Affect AML?How Do Doctors Assess Fitness for AML Chemotherapy?How is Venetoclax Given for Acute Myeloid Leukemia?How Long Does Chemo Brain Last After AML Treatment?What Are AML Induction & Consolidation Therapies?What Are AML Skin and Gum Symptoms? | Inciteful MedWhat Conditions Mimic Acute Myeloid Leukemia?What Does MRD Negative Mean in Acute Myeloid Leukemia?What is cGVHD After an AML Stem Cell Transplant?What Is a Day 14 Bone Marrow Biopsy in AML Treatment?

References

References (25)
  1. 1

    Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.

    Döhner H, Wei AH, Appelbaum FR, et al.

    Blood 2022; (140(12)):1345-1377 doi:10.1182/blood.2022016867.

    PMID: 35797463
  2. 2

    Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.

    Salman H

    Cancers 2024; (16(16)) doi:10.3390/cancers16162915.

    PMID: 39199685
  3. 3

    Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.

    Song GY, Kim HJ, Kim T, et al.

    Scientific reports 2024; (14(1)):8517 doi:10.1038/s41598-024-57295-5.

    PMID: 38609396
  4. 4

    Reclassification of Acute Myeloid Leukemia According to the 2022 World Health Organization Classification and the International Consensus Classification Using Open-Source Data.

    Yun J

    Annals of laboratory medicine 2025; (45(2)):170-177 doi:10.3343/alm.2024.0194.

    PMID: 39676421
  5. 5

    Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.

    Falini B, Dillon R

    Blood cancer discovery 2024; (5(1)):8-20 doi:10.1158/2643-3230.BCD-23-0144.

    PMID: 37917833
  6. 6

    Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.

    Tarlock K, Sulis ML, Chewning JH, et al.

    Transplantation and cellular therapy 2022; (28(9)):530-545 doi:10.1016/j.jtct.2022.06.005.

    PMID: 35717004
  7. 7

    Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.

    Pinar IE, Celik S, Polat MG, et al.

    BMC cancer 2025; (25(1)):1546 doi:10.1186/s12885-025-14987-z.

    PMID: 41073967
  8. 8

    Comparison of autologous hematopoietic cell transplantation, matched sibling donor hematopoietic cell transplantation, and chemotherapy in patients with favorable- and intermediate-risk acute myeloid leukemia.

    Wang M, Chen S, Zhang Q, et al.

    Frontiers in immunology 2024; (15()):1511057 doi:10.3389/fimmu.2024.1511057.

    PMID: 39845970
  9. 9

    Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.

    Lo MY, Tsai XC, Lin CC, et al.

    American journal of hematology 2023; (98(5)):760-769 doi:10.1002/ajh.26892.

    PMID: 36861732
  10. 10

    FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML.

    Stancioaica MC, Coriu D, Ghiaur G

    Cancers 2025; (17(21)) doi:10.3390/cancers17213415.

    PMID: 41228209
  11. 11

    Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.

    Sasaki K, Kantarjian HM, Kadia T, et al.

    Cancer 2019; (125(21)):3755-3766 doi:10.1002/cncr.32387.

    PMID: 31310323
  12. 12

    Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022.

    Berdel AF, Ronnacker J, Wenge DV, et al.

    Blood neoplasia 2026; (3(1)):100181 doi:10.1016/j.bneo.2025.100181.

    PMID: 41509995
  13. 13

    Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

    Bill M, Eckardt JN, Döhner K, et al.

    Leukemia 2026; (40(1)):63-71 doi:10.1038/s41375-025-02781-6.

    PMID: 41145671
  14. 14

    Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

    Mecklenbrauck R, Villaverde Ramiro A, Sträng E, et al.

    Leukemia 2026; (40(3)):622-629 doi:10.1038/s41375-026-02874-w.

    PMID: 41663622
  15. 15

    Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

    Marvin-Peek J, Gilbert JS, Pollyea DA, DiNardo CD

    American journal of hematology 2024; (99(9)):1790-1801 doi:10.1002/ajh.27434.

    PMID: 39016070
  16. 16

    Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.

    Wei AH, Tiong IS

    Blood 2017; (130(23)):2469-2474 doi:10.1182/blood-2017-08-784066.

    PMID: 29051180
  17. 17

    Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group.

    Wen Q, Jiang C, Liu X, et al.

    Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2025; (37(3)):417-431 doi:10.21147/j.issn.1000-9604.2025.03.10.

    PMID: 40642494
  18. 18

    Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP.

    Bazarbachi A, Galimard JE, Dalle IA, et al.

    American journal of hematology 2025; (100(8)):1374-1386 doi:10.1002/ajh.27726.

    PMID: 40445901
  19. 19

    European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.

    Bataller A, Garrido A, Guijarro F, et al.

    Blood advances 2022; (6(4)):1193-1206 doi:10.1182/bloodadvances.2021005585.

    PMID: 34911079
  20. 20

    Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.

    Short NJ, Ong F, Ravandi F, et al.

    Blood advances 2023; (7(14)):3573-3581 doi:10.1182/bloodadvances.2022009632.

    PMID: 37104058
  21. 21

    Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review.

    Ma C, Lang H, Chen Y, et al.

    Anti-cancer drugs 2024; (35(6)):548-555 doi:10.1097/CAD.0000000000001594.

    PMID: 38502829
  22. 22

    DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.

    Dillon LW, Gui G, Page KM, et al.

    JAMA 2023; (329(9)):745-755 doi:10.1001/jama.2023.1363.

    PMID: 36881031
  23. 23

    Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.

    Cloos J, Ngai LL, Heuser M

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):682-690 doi:10.1182/hematology.2023000454.

    PMID: 38066915
  24. 24

    Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.

    Jentzsch M, Bischof L, Backhaus D, et al.

    Blood advances 2022; (6(15)):4570-4580 doi:10.1182/bloodadvances.2022007168.

    PMID: 35605254
  25. 25

    Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide.

    Villalba M, Montoro J, Balaguer-Roselló A, et al.

    Haematologica 2026; (111(2)):508-517 doi:10.3324/haematol.2025.287860.

    PMID: 40905088

This page explains AML risk categories for educational purposes only and does not constitute medical advice. Always discuss your specific genetic test results and treatment plan with your oncologist.

Get notified when new evidence is published on Acute myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.